Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04348136 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Mar 13, 2024, no change to tracked fieldsv5-v7
  2. Study sites: 19 to 20v4
  3. Primary endpoints: 6 to 25
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints shortened, about 240 words
    • Study title expanded, about 1 word
    v3
  4. Primary and study completion dates: Jun 30, 2021 to Mar 31, 2030
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.
Trial Details
NCT Number NCT04348136
Lead Sponsor JCR Pharmaceuticals Co., Ltd.
Conditions
(from sponsor)		 Mucopolysaccharidosis II
Related terms Mucopolysaccharidosis II
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov